This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

TherapeuticsMD Poster Wins First-Place Prize At The North American Menopause Society 2013 Annual Meeting

Stocks in this article: TXMD

TherapeuticsMD, Inc. (NYSE MKT: TXMD) announced today that it received the first-place prize for its poster at the The North American Menopause Society (NAMS) 2013 Annual Meeting recently held in Dallas. The poster detailed findings on the first investigational combination 17β-estradiol and progesterone capsule that may have overcome the well-recognized difficulties of achieving good bioavailability with oral administration of these hormones in combination. TherapeuticsMD is developing this compound, TX 12-001-HR, for FDA review.

Bioavailability of TX 12-001-HR, a capsule containing both 17β-estradiol and progesterone for oral use, was found to be similar to that of the standard reference products for the human hormones estradiol (Estrace ®) and progesterone (Prometrium ®), when taken concurrently. The poster, which was presented by James H. Pickar, M.D., Adjunct Associate Professor of Obstetrics and Gynecology, Columbia University College of Physicians & Surgeons in New York, described findings from a phase 1 study.

"NAMS congratulates TherapeuticsMD on its poster design award. Its poster was selected by an independent poster review committee. NAMS is pleased that so many outstanding research posters on women’s health and menopause were presented at our annual meeting," said Dr. Margery Gass, executive director of The North American Menopause Society.

Posters were evaluated on the basis of five criteria: appropriateness of study design, whether the conclusion flows from the results, overall quality of the science, impact of the study on the field of menopause, and visual appeal of the poster. Each category was rated on a 1-to-5 scale, with 1 = poor, 2 = fair, 3 = satisfactory, 4 = good, and 5 = excellent. The total score for each poster was the sum of the scores given for each of the criteria. Each poster was judged by three experts. The 113 poster presentations evaluated by a judging panel of 23 medical experts were eligible for up to four prizes, with first- and second-place winners receiving cash awards. TherapeuticsMD donated its first-place prize of $1,000 to NAMS.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,654.52 -18.08 -0.10%
S&P 500 2,052.74 +0.92 0.04%
NASDAQ 4,763.6120 +5.7330 0.12%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs